Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.00 | N/A | -100.00% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.00 | N/A | -100.00% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management's tone was defensive, highlighting difficulties in the current market environment. They did not offer any forward guidance.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The company acknowledged challenges in meeting earnings expectations.
Ligand Pharmaceuticals reported zero earnings per share, which was a significant miss. The lack of revenue figures and guidance contributed to a negative stock reaction, with shares falling 3.55%. Investors may be concerned about the company's performance and future outlook given the absence of detailed financial metrics.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
NRG ENERGY INC
Aug 2, 2010